Drug Profile
Levomequitazine - Pierre Fabre
Alternative Names: (-)-mequitazine; (S)-mequitazine; L-mequitazine; V0114; V0114CPLatest Information Update: 10 Aug 2021
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antiallergics; Phenothiazines; Sedating antihistamines; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Perennial allergic rhinitis; Seasonal allergic rhinitis
Most Recent Events
- 10 Aug 2021 Discontinued - Phase-III for Perennial allergic rhinitis in Spain, Latvia, Austria, United Kingdom, Estonia, Lithuania, Finland, Czech Republic (PO) (Pierre Fabre pipeline, August 2021)
- 10 Aug 2021 Discontinued - Phase-III for Seasonal allergic rhinitis in Czech Republic, Estonia, France, Latvia, Poland, Denmark, Spain, Italy, Hungary, Belgium, Lithuania, Slovakia, Germany (PO) (Pierre Fabre pipeline, August 2021)
- 19 May 2009 Pierre Fabre completes a phase III trial in Seasonal allergic rhinitis in Poland, Belgium (PO) (EudraCT2008-008734-36)